Bruner DW, et al. - In this phase 3 randomized clinical trial of 962 trial participants, researchers investigated the differences in health-related quality of life between men with low-risk prostate cancer who are treated with hypofractionated vs conventional radiotherapy. Outcomes suggest treatment with hypofractionated radiotherapy as noninferior to conventional radiotherapy in these men in terms of disease-free survival with no differences in prostate cancer–specific (eg, bowel, bladder, sexual) and general quality of life, as well as in anxiety and depression. This study provides level 1 evidence supporting hypofractionated radiotherapy as a new practice standard for men with localized prostate cancer.